De novo AML patients with favourable-intermediate karyotype may benefit from the addition of low-dose gemtuzumab ozogamicin (GO) to fludarabine, Ara-C and idarubicin (FLAI): a contribution to the reopened "GO question".
about
Effect of adding gemtuzumab ozogamicin to induction chemotherapy for newly diagnosed acute myeloid leukemia: a meta-analysis of prospective randomized phase III trials.High feasibility and antileukemic efficacy of fludarabine, cytarabine, and idarubicin (FLAI) induction followed by risk-oriented consolidation: A critical review of a 10-year, single-center experience in younger, non M3 AML patients.
P2860
De novo AML patients with favourable-intermediate karyotype may benefit from the addition of low-dose gemtuzumab ozogamicin (GO) to fludarabine, Ara-C and idarubicin (FLAI): a contribution to the reopened "GO question".
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
De novo AML patients with favo ...... to the reopened "GO question".
@en
De novo AML patients with favo ...... to the reopened "GO question".
@nl
type
label
De novo AML patients with favo ...... to the reopened "GO question".
@en
De novo AML patients with favo ...... to the reopened "GO question".
@nl
prefLabel
De novo AML patients with favo ...... to the reopened "GO question".
@en
De novo AML patients with favo ...... to the reopened "GO question".
@nl
P2093
P2860
P1433
P1476
De novo AML patients with favo ...... to the reopened "GO question"
@en
P2093
Carlo Marani
Chiara Ghiggi
Daniele Avenoso
Davide Lovera
Enrico De Astis
Fabio Cruciani
Filippo Ballerini
Giordana Pastori
Laura Mitscheunig
Marco Gobbi
P2860
P304
P356
10.1007/S00277-013-1780-7
P50
P577
2013-05-18T00:00:00Z